The capital turnover (annual revenue relative to shareholder's equity) for DPLO is 39.73 -- better than 99.4% of US stocks.
DPLO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.02 -- higher than just 0.64% of US-listed equities with positive expected earnings growth.
Over the past twelve months, DPLO has reported earnings growth of -2,110.81%, putting it ahead of just 0.74% of US stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to NA are NCSM, CIR, AFH, SMIT, and TSRI.
Diplomat Pharmacy operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company was founded in 1975 and is focused in Flint, Michigan.